Bojena Bitman

Minimally Important Difference of Health Assessment Questionnaire in Psoriatic Arthritis: Relating Thresholds of Improvement in Functional Ability to Patient-rated Importance and Satisfaction

Philip J. Mease, J. Michael Woolley, Bojena Bitman et al. · The Journal of Rheumatology · 2011 · 125 citations · Full text

Pharmacy, Chronic Disease Control, Functional Assessment +16

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Tian Zhang, Michael R. Harrison, Peter H. O’Donnell et al. · Cancer · 2020 · 35 citations · Full text

Medicine, Oncology, Pharmacology +17

Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial

Jeffrey R. Curtis, Shuo Yang, Lang Chen et al. · Annals of the Rheumatic Diseases · 2011 · 33 citations

Medicine, Pharmacology, Pharmacotherapy +17

Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports

Michele Hooper, Deborah Wenkert, Bojena Bitman et al. · Pediatric Rheumatology · 2013 · 26 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Impact of Etanercept on Work and Activity Impairment in Employed Moderate to Severe Rheumatoid Arthritis Patients in the United States

Devon Hone, Annie Cheng, Crystal Watson et al. · Arthritis Care & Research · 2013 · 25 citations

Medicine, Clinical Sciences, Internal Medicine +17